Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

The aim of this study is to evaluate the use of a fixed dose of 3.66 mcg of follitropin delta (Rekovelle) on ovarian response during ovarian stimulation for intrauterine insemination (IUI). The assumption is that this fixed dose will be effective while minimizing the risk of multiple pregnancies. A recent study demonstrated the efficacy of follitropin delta for ovarian stimulation in IUI, and it has been approved in France for controlled ovarian stimulation in assisted reproductive techniques such as in vitro fertilization (IVF) and IVF with intracytoplasmic sperm injection (ICSI). With an adapted dose of Rekovelle for patients with regular menstrual cycles, ovarian stimulation is optimized from the first attempt, promoting the development of two follicles to improve pregnancy chances while reducing the risk of multiple pregnancies. This approach aims to achieve pregnancy faster and provide a more comfortable treatment experience.

Start Date17 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Intercommunal Créteil

[+1]

NCT06997900

/ RecruitingPhase 2

Menopur And Rekovelle Combination Study Version 2.0

The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:
- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?
Researchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes
Participants will:
* Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight
* Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels
* Undergo standard IVF procedures including egg retrieval and embryo assessment

Start Date04 Jul 2025

Sponsor / Collaborator

Clinique Ovo, Inc.

[+1]

NCT06561958

/ Active, not recruitingNot Applicable

Prospective, Multi-country, Non-Interventional Study to Investigate REKOVELLE for Ovarian Stimulation: the Effectiveness, Safety, and Patterns Of Use for Asian Women in Real World Practice

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Start Date27 Aug 2024

Sponsor / Collaborator

Ferring Pharmaceuticals SA

100 Clinical Results associated with Follitropin delta

100 Translational Medicine associated with Follitropin delta

100 Patents (Medical) associated with Follitropin delta

1,232

Literatures (Medical) associated with Follitropin delta

01 Mar 2026·FERTILITY AND STERILITY

Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial

Article

Author: Rodriguez, Ignacio ; Polyzos, Nikolaos P ; García-Martinez, Sandra ; Neves, Ana Raquel ; Donno, Valeria

OBJECTIVE:

The study aimed to compare the efficacy, in terms of mature oocytes, of dual trigger vs. agonist alone in good-prognosis patients undergoing elective fertility preservation.

DESIGN:

Randomized, controlled, single-center, superiority clinical trial.

SUBJECTS:

A total of 109 women were enrolled in this study between October 2021 and April 2023 with a 1:1 allocation. Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.

INTERVENTION:

Controlled ovarian stimulation was performed using 225-300 IU/d of follitropin α or β or 15-20 μg of follitropin δ, tailored to ovarian reserve and weight. Luteinizing hormone surge was suppressed through a progestin-primed ovarian stimulation protocol, with oral administration of micronized progesterone (200 mg daily) from the beginning of ovarian stimulation until the trigger day. As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).

MAIN OUTCOME MEASURES:

The primary endpoint was the number of metaphase II (MII) oocytes retrieved after final oocyte maturation with dual trigger and GnRH-a trigger in patients undergoing elective fertility preservation.

RESULTS:

Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a). No statistically significant differences were found regarding the total number of oocytes nor MII oocytes retrieved between the dual trigger and GnRH-a groups (9.22 ± 5.11 vs. 9.56 ± 5.16 [estimated mean difference, -0.34 {95% confidence interval, -2.29 to 1.61}] and 7.31 ± 4.63 vs. 7.94 ± 4.39 group [estimated mean difference, -0.64 {95% confidence interval, -2.07 to 0.80}], respectively). Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger. Notably, neither group exhibited any case of ovarian hyperstimulation syndrome.

CONCLUSION:

In patients undergoing fertility preservation, adding human chorionic gonadotropin to GnRH-a for triggering final oocyte maturation is not superior to the administration of GnRH-a alone in terms of MII oocytes. Therefore, the selection of the trigger method should be based on both patients' and clinicians' preferences, with a focus on patients' safety and convenience.

01 Feb 2026·REPRODUCTIVE BIOMEDICINE ONLINE

Disentangling the current role of LH activity in assisted reproduction: from biology to patient personalization

Review

Author: Bellver, José ; Fabregues, Francisco ; Serna, José ; Espinós, Juan José ; Bosch, Ernesto

The importance of determining the precise role of gonadotrophins in assisted reproductive technology (ART) is increasingly recognized, as optimizing ovarian stimulation protocols is crucial for improving outcomes. Recent advances in reproductive biology highlight the multifaceted functions of LH, revealing a complex interplay between its endocrine actions and local ovarian mechanisms. Traditionally, LH was primarily associated with its role in triggering ovulation and supporting the corpus luteum. Accumulating evidence, however, suggests that LH also influences follicular steroidogenesis, oocyte maturation and endometrial receptivity. Despite these insights, the role of LH in ovarian stimulation remains under debate, particularly outside of patients with hypogonadotropic hypogonadism, characterized by hypothalamic amenorrhoea. Notably, recent molecular and clinical evidence supports the benefits of including LH activity in ovarian stimulation protocols for select patient groups. LH activity can be derived from human menopausal gonadotrophin, which contains both FSH and LH activity, with LH primarily driven by HCG; recombinant LH (rLH), or recombinant FSH + LH (rFSH + rLH). This review clarifies the evolving role of LH activity in ART, bridging foundational biological insights with the emerging paradigm of patient-specific treatment strategies to optimize reproductive outcomes.

01 Jan 2026·FERTILITY AND STERILITY

Ovarian stimulation with follitropin delta is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials

Article

Author: Doody, Kevin J ; Scheiber, Michael D ; Foster, Eric D ; Grover, Sarah A ; Heiser, Patrick W

OBJECTIVE:

To demonstrate the efficacy and safety of follitropin delta (recombinant follicle-stimulating hormone produced from the human cell line PER.C6) for ovarian stimulation in patients aged 18-34 and 35-42 years undergoing in vitro fertilization or intracytoplasmic sperm injection treatment in the United States.

DESIGN:

Two randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (RITA-1 and RITA-2).

SUBJECTS:

A total of 1,165 patients (578 women aged 18-34 years in RITA-1 and 587 women aged 35-42 years in RITA-2), randomized 10:1 to follitropin delta or placebo.

INTERVENTION:

Ovarian stimulation with follitropin delta at a fixed starting dose (12 μg/d for patients aged <35 years and 15 μg/d for patients aged ≥35 years) for the first 4 stimulation days and subsequent dose adjustments as needed, or placebo as a reference group, in a gonadotropin-releasing hormone antagonist cycle.

MAIN OUTCOME MEASURES:

Cumulative ongoing pregnancy rate after fresh and cryopreserved cycles initiated within 12 months from start of ovarian stimulation.

RESULTS:

The cumulative ongoing pregnancy rates with follitropin delta were 64.0% in patients aged <35 years (RITA-1) and 43.9% in patients aged ≥35 years (RITA-2) vs. 0 with placebo, thus establishing superiority of follitropin delta to placebo (RITA-1, difference, 64.0% [95% confidence interval, 56.9%-68.1%]; RITA-2, difference, 43.9% [95% confidence interval, 37.0%-48.2%]). The cumulative live birth rates with follitropin delta were 62.5% in patients aged <35 years and 42.4% in patients aged ≥35 years. In the fresh transfer cycle, the ongoing pregnancy rates with follitropin delta were 49.5% in patients aged <35 years and 34.8% in patients aged ≥35 years, and the live birth rates were 48.2% and 33.9%, respectively. In cryopreserved transfer cycles, the ongoing pregnancy rates with follitropin delta were 44.2% in patients aged <35 years and 31.2% in patients aged ≥35 years, and the live birth rates were 42.8% and 29.9%, respectively. The incidence rates of ovarian hyperstimulation syndrome in the fresh cycle were 3.8% in patients aged <35 years and 2.4% in patients aged ≥35 years after treatment with follitropin delta.

CONCLUSION:

Follitropin delta, dosed on the basis of maternal age, is an effective and safe therapeutic for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection patients.

TRIAL REGISTRATION:

For RITA-1, NCT03740737 (ClinicalTrials.gov), registered on October 24, 2018, first subject enrolled on October 26, 2018. For RITA-2, NCT03738618 (ClinicalTrials.gov), registered on October 24, 2018, first subject enrolled on October 29, 2018.

News (Medical) associated with Follitropin delta

09 Mar 2026

·www.fiercepharma.com

Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application

Before Incyte, Novo Nordisk's legacy Catalent site triggered complete response letters for Regeneron and Scholar Rock. Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application, with Incyte announcing Friday that the FDA handed over a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer (NSCLC).The rejection was not related to any efficacy or safety concerns but rather inspection findings at a fill-finish facility—specifically, the former Catalent plant in Bloomington, Indiana, which is now owned by Novo as part of Novo Holdings’ $16.5 billion acquisition of the CDMO in 2024.The setback comes more than a year after Incyte detailed a 25% reduction in the risk of death for a combination of Zynyz and chemotherapy versus chemo alone among patients with newly diagnosed metastatic NSCLC in the phase 3 Pod1um-304 trial. By clearing that clinical hurdle, Incyte was poised to enter the lucrative first-line NSCLC market, only to be tripped up now by a manufacturing site that has created headaches for several biopharma companies.Incyte joins a growing list of drugmakers that have seen regulatory timelines delayed by compliance issues at Novo’s Indiana site, referred to as Catalent Indiana in Incyte’s filing. Last year, the facility yielded a pair of CRLs for Regeneron, with one for high-dose Eylea and the other for blood cancer bispecific odronextamab.Scholar Rock also received a CRL last year thanks to production issues at the ex-Catalent plant, with the company’s spinal muscular atrophy candidate apitegromab denied approval in September. Problems at the Indiana plant culminated in an FDA warning letter in November. During an inspection in the summer of 2025, the FDA found that the facility failed to properly investigate more than 20 deviations linked to possible contamination of drug product from mammalian hair contamination in or around the stopper region of vials.In a March 9 statement to Fierce Pharma, a Novo spokesperson said the company is “actively engaging with the agency to address its findings.”The FDA issued its CRL to Incyte on Feb. 27. The agency delivered another manufacturing-related CRL on the same day to Ferring Pharmaceuticals, hitting the firm’s human recombinant follicle simulating hormone follitropin delta (FE 999049), which is being developed for women undergoing uncontrolled ovarian stimulation. The drug is approved under the brand name Rekovelle in several international markets, such as the EU. Ferring’s trouble doesn’t seem to come from the Catalent Indiana site. While the Novo manufacturing site’s censure is not related to a specific product, the Ferring CRL followed deficiencies uncovered during a pre-license inspection of a facility, which led to an FDA Form 483, according to the CRL published (PDF) by the FDA.Fierce Pharma has reached out to Ferring for comment. As to Incyte, the impact of the CRL is limited. Although first-line NSCLC is the largest indication in oncology, Merck & Co.’s deeply entrenched Keytruda leaves little room for another PD-1 in most developed markets. Zynyz got its initial FDA nod last year, becoming the first treatment specifically approved in first-line anal cancer. Incyte also announced Friday that the European Commission has authorized the drug for the same use.Following its May 2025 nod, Zynyz brought in $66.4 million in sales last year. Incyte’s former CEO Hervé Hoppenot previously told Fierce that the company does not expect the PD-1 inhibitor to be a major revenue driver but noted that U.S. approvals may be used as reference for regulators at certain emerging markets. Editor's Note: The story was updated at 2:45 p.m. ET with a statement from Novo Nordisk.

Drug ApprovalPhase 3AcquisitionAccelerated Approval

03 Dec 2025

·www.fiercepharma.com

Workplaces labor to keep staff as fertility support falls short, Ferring survey finds

More than 20% of employees said they feel unsupported in the workplace regarding fertility treatment. A Ferring Pharmaceuticals survey has found 39% of people undergoing fertility treatment are at least considering leaving their jobs, leading the drugmaker to question whether companies are doing enough to support employees. Ferring funded the survey and worked with Fertility Matters at Work and This Can Happen, groups that offer workplace support, on the project. Having initially targeted the U.K., the survey expanded to include Australia, France, Japan and Poland and to cover more than 3,600 employees and employers. The goal was to explore how fertility challenges affect people at work and what employers can offer.Two-thirds of respondents who have faced fertility challenges said their workplaces don’t offer support for employees undergoing fertility treatment. Support is rarest in France, where 88% of respondents said their employers lacked initiatives to help workers receiving fertility treatment.The survey found 60% of respondents lacked clear entitlement to time off for fertility appointments. The situation led people undergoing fertility treatment to record time off for appointments as paid, unpaid or annual leave. Almost 20% of respondents said the lack of flexibility led them to take sick leave. The presence or absence of support is informing decisions about where to work. Beyond finding that 39% of people undergoing fertility treatment are leaving or considering quitting their jobs, the survey revealed widespread interest in roles that provide fertility support. Almost three-quarters of people who are experiencing fertility challenges would be attracted to roles that provide support.While 75% of employers said they recognize fertility treatment as a significant life event, only 27% of employees who have experienced fertility challenges agree. More than 20% of employees said they feel unsupported, and 36% have felt pressure from their employer to work while undergoing treatment or investigations. Mental well-being is a particular concern for people undergoing fertility treatment.Signs suggest uptake of fertility treatment could increase. Babies conceived using assisted reproductive technology accounted for 2.6% of births in the U.S. in 2022. The figure rises to around 10% in Denmark and 12% in Spain. President Donald Trump acted to increase access to fertility care in the U.S. in October, including by inking a drug pricing deal with Merck KGaA's EMD Serono.Like EMD Serono, Ferring sells fertility drugs. Ferring’s portfolio includes the recombinant human follicle-stimulating hormone Rekovelle, which competes with drugs including the Gonal-f product covered by Trump’s deal with EMD Serono.

02 Jul 2025

·pipelinereview.com

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta

PARIS, France I July 02, 2025 I Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction . These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved. Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8 , particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8 Key Findings: Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: “No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta.” Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: “The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities.” About GnRH protocols Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8 About Follitropin Delta (Rekovelle ® ) Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman’s AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at www.ferring.com , or connect with us on LinkedIn , Instagram , YouTube , Facebook and X . REFERENCES 1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020 2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022 3 – Clinical Trials.gov page: https://clinicaltrials.gov/study/NCT05263388 (Accessed June 2025) 4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396. 5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482. 6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17. 7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29. 8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578. SOURCE: Ferring Pharmaceuticals

Phase 3Clinical ResultDrug Approval

100 Deals associated with Follitropin delta

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G03GA10	DB00066

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infertility	Canada	Ferring, Inc.	22 Mar 2018
Infertility, Female	Australia	Ferring Pharmaceuticals Pty Ltd.	21 Sep 2017
Ovarian Stimulations	European Union	Ferring Pharmaceuticals A/S	12 Dec 2016
Ovarian Stimulations	Iceland	Ferring Pharmaceuticals A/S	12 Dec 2016
Ovarian Stimulations	Liechtenstein	Ferring Pharmaceuticals A/S	12 Dec 2016
Ovarian Stimulations	Norway	Ferring Pharmaceuticals A/S	12 Dec 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Hyperstimulation Syndrome	Phase 3	China	Ferring Pharmaceuticals A/S	01 Dec 2017
Ovarian Hyperstimulation Syndrome	Phase 3	South Korea	Ferring Pharmaceuticals A/S	01 Dec 2017
Ovarian Hyperstimulation Syndrome	Phase 3	Taiwan Province	Ferring Pharmaceuticals A/S	01 Dec 2017
Ovarian Hyperstimulation Syndrome	Phase 3	Vietnam	Ferring Pharmaceuticals A/S	01 Dec 2017
Female infertility of tubal origin	Phase 3	Belgium	Ferring Pharmaceuticals A/S	01 Oct 2013
Female infertility of tubal origin	Phase 3	Brazil	Ferring Pharmaceuticals A/S	01 Oct 2013
Female infertility of tubal origin	Phase 3	Canada	Ferring Pharmaceuticals A/S	01 Oct 2013
Female infertility of tubal origin	Phase 3	Czechia	Ferring Pharmaceuticals A/S	01 Oct 2013
Female infertility of tubal origin	Phase 3	Denmark	Ferring Pharmaceuticals A/S	01 Oct 2013
Female infertility of tubal origin	Phase 3	France	Ferring Pharmaceuticals A/S	01 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06173869 (COCO, CTgov)	Phase 3	Female infertility of tubal origin \| Infertility, Female	301	FE 999049 (FE 999049)	xxgtafcvtj(kmglznxrwq) = blnwibuwmt cgsmdcytxl (vgmmucmpbc, 5.2) View more	-	12 Feb 2026
				GONAL-F (GONAL-F)	xxgtafcvtj(kmglznxrwq) = jtrkqfurik cgsmdcytxl (vgmmucmpbc, 5.3) View more
NCT05263388 (ADAPT-1, CTgov)	Phase 3	Female infertility of tubal origin \| Infertility	302	Follitropin Delta (REKOVELLE (Follitropin Delta))	jcrvnxhmbg(tdbeajcejo) = dqnkchsnxp sncfmwtvkb (irmdseqroe, dguatkyjul - tprxtjoyap) View more	-	02 Apr 2025
				GONAL-F (Follitropin Alfa) (GONAL-F (Follitropin Alfa))	jcrvnxhmbg(tdbeajcejo) = pslkqwuoxg sncfmwtvkb (irmdseqroe, xlsaaldfcr - tirtbryofy) View more
NCT05103228 (CTgov)	Not Applicable	Infertility \| Diminished ovarian reserve \| Ovarian Diseases	190	human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Lower Gonadotropin Dose Stimulation)	dsnqxysxvh = wjazkqhacl vayysaoziy (ygrtbuvdhd, qxilvdmefu - ouxmgsuscl) View more	-	13 Dec 2024
				human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Higher Gonadotropin Dose Stimulation)	dsnqxysxvh = ixqcxbznua vayysaoziy (ygrtbuvdhd, cetqsxerjz - agcquygikx) View more
NCT03809429 (BEYOND, CTgov)	Phase 3	Infertility, Female	437	GONAPEPTYL+FE 999049+GnRH agonist (FE 999049 + GnRH Agonist (GONAPEPTYL))	pjhiyltunl(dhspqihnqz) = wtyjowrozm sbamooimbg (nzlxvcvjep, 5.9) View more	-	13 May 2024
				GnRH antagonist+CETROTIDE+FE 999049 (FE 999049 + GnRH Antagonist (CETROTIDE))	pjhiyltunl(dhspqihnqz) = fyuaiasiyu sbamooimbg (nzlxvcvjep, 5.5) View more
NCT03809429 (BEYOND, Pubmed \| Hum Reprod) Manual	Phase 3	Infertility, Female AMH ≤35 pmol/l	437	follitropin deltaGONAPEPTYL (GnRH agonist protocol)	jsfhglhyae(pkbpyabdry) = ogtgghyxrq dhlzesiwyb (wdrjcuvyyb, 5.9) View more	Positive	09 May 2024
				FE 999049follitropin deltaCETROTIDE (GnRH antagonist protocol)	jsfhglhyae(pkbpyabdry) = pzytoqnned dhlzesiwyb (wdrjcuvyyb, 5.5) View more
NCT03740737 (RITA-1, CTgov)	Phase 3	Female infertility of tubal origin \| Infertility \| Infertility, Male	579	Follitropin delta (FE 999049 (Follitropin Delta))	wugyyforhu = slaheybxbj kqpekadjxl (yptivbketw, hinsdfuprt - ftgvksrnvw) View more	-	18 Jan 2024
				Placebo (Placebo)	wugyyforhu = uihfghfggy kqpekadjxl (yptivbketw, qlpnnqephm - ydaadjlayn) View more
NCT03738618 (RITA-2, CTgov)	Phase 3	Female infertility of tubal origin \| Infertility, Female	588	Follitropin delta (FE 999049 (Follitropin Delta))	yawanmltyh = turitfwyrv fstlsdywzk (hlrokayvlf, rmscxqyqvv - tgbuviudqy) View more	-	18 Jan 2024
				Placebo (Placebo)	yawanmltyh = wrrqttbohn fstlsdywzk (hlrokayvlf, rmieuvpogb - bcidycxwox) View more
NCT04150861 (Pubmed)	Phase 1	-	24	Follitropin delta 12 μg	vnzfludbhq(fwfdjniieh) = frwxkcsimm oeeburvrhq (zyjfiuqvab ) View more	-	07 Dec 2022
				Follitropin delta 18 μg	vnzfludbhq(fwfdjniieh) = ttlcztvyxt oeeburvrhq (zyjfiuqvab ) View more
NCT03393780 (PROFILE, Pubmed \| Front Endocrinol (Lausanne))	Not Applicable	Ovarian Stimulations	944	Follitropin delta	wrbidzmnja(brwwrqefpe) = most cases of OHSS were of mild or moderate intensity (n=30 [3.2%]) daodjwfjbn (tnthbthkqq )	Positive	01 Jan 2022
NCT01956110 (NCT03228680, NCT01956110, Pubmed \| Reprod Biomed Online)	Phase 3	-	800	follitropin delta (Japanese women)	oausiikzgc(jakuegkdep) = kzupjanuej zhgkkodxby (ndcytgxgxs )	-	23 Sep 2021
				follitropin delta (White women)	oausiikzgc(jakuegkdep) = jmvwsqrykf zhgkkodxby (ndcytgxgxs )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis